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Abstract: Chronic obstructive pulmonary disease (COPD) is a global health problem. Being a 
progressive disease characterized by inﬂ  ammation and predominantly caused by tobacco smok-
ing, it deteriorates pulmonary and skeletal muscle functioning, and reduces physical behavior, 
societal participation and quality of life. During the last two decades studies were focused on the 
airway and systemic inﬂ  ammation, oxidative stress, and airway and/or parenchymal remodel-
ing. Macrophages, neutrophils and T cells are thought to be important key players, as well as 
structural cells like ﬁ  broblasts, epithelial, endothelial and smooth muscle cells. Mediators and 
proteins including cytokines, chemokines, growth factors, proteinases, and oxidants seem to be 
involved differentially in its pathogenesis. Current pharmacological treatments are directed to 
reducing airway inﬂ  ammation, boosting the endogenous levels of anti-oxidants and relieving 
airway contraction and sputum production. Most agents were primarily used for treating asthma. 
But in contrast to asthma, these treatments are not very effective in COPD. As a result, novel 
more speciﬁ  cally acting interventional drugs with less side effects are being developed to treat 
chronic inﬂ  ammatory diseases, including COPD. This review highlights studies on novel or 
potential drug antioxidants such as dietary antioxidants supplementation, N-acetyl-L-cysteine, 
N-acystelyn, endosteine, antioxidant enzyme mimetics, and anti-inﬂ  ammatory agents like antago-
nists of cytokines, such as tumor necrosis factor (TNF)-α, CXCL8, and CCL2, and inhibitors of 
signal transduction proteins including phosphodiesterase 4, MAPK p38, Pl-3k, and NFκB.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a global health problem. According 
to estimates of the World Health Organization (WHO) about 80 million patients over 
the world suffered from COPD in 2005, whereas it accounts for 5% of all deaths. COPD 
is currently the 4th major cause of death worldwide. The prevalence is estimated to 
be about 1% worldwide, but is about 2 times higher in Western societies, and often 
underestimated due to un- or misdiagnosis (Pauwels and Rabe 2004; Menezes et al 
2005; Lindberg et al 2006). The burden of COPD for the patient is high as patients 
experience a poorer quality of life, suffer from comorbidites (3.7 comorbidities per 
patient), and direct healthcare costs range from 0.28 billion euros in the Netherlands (in 
2000) to 20.9 billion dollars in the USA (in 2004) (Hynninen et al 2005; Hoogendoorn 
et al 2006; Jones 2006; Sin et al 2006).
COPD is a progressive disease which is yet not curable. In Western countries the major 
cause is tobacco smoking, whereas in developing countries also indoor pollution eg, from 
cooking fuel biomass burning is a cause. Other risk factors for COPD include genetic 
predisposition, occupational and environmental exposure, and asthma. More than 90% 
of patients with COPD are smokers (Snider 1989), but at least 10%–20% of the smokers 
develop COPD pointing at an additional risk factor, eg, gene susceptibility. Among the 
genetic susceptibility factors are polymorphisms in genes coding for (anti-) proteases like 
alpha-1 antitrypsin (A1AT) (accounting for at least 5% of COPD cases) and a disinte-International Journal of COPD 2007:2(3) 206
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grin and metalloproteinase 33 (ADAM33), genes coding for 
antioxidant enzymes like glutamate cysteine ligase, epoxide 
hydrolase, glutathione-S-transferase, and superoxide dismutase 
(SOD) 3, or genes coding for cytokines like tumor necrosis factor 
alpha (TNFα) and transforming growth factor beta 1 (TGFβ1) 
(Harrison et al 1997; Keatings et al 2000; Sandford et al 2001; 
Kucukaycan et al 2002; Celedon et al 2004; Gosman, Boezen 
et al 2006; Young et al 2006).
Since chronic pulmonary inﬂ  ammation and oxidative 
stress are important characteristics in the pathogenesis 
of COPD, this paper discusses the role of inﬂ  ammatory 
mediators and oxidants and rational of anti-inﬂ  ammatory 
and anti-oxidant therapeutic intervention in the management 
of COPD.
Pathophysiology
COPD is an inﬂ  ammatory chronic lung disease that shows 
a largely irreversible lung function decline, and can be 
classiﬁ  ed into 4 classes of severity based on lung func-
tion [GOLD Guidelines]. Emphysema, chronic bronchitis 
with airway obstruction, and small airways disease are the 
distinct phenotypes of COPD, but most patients show a 
combination. Emphysema is characterized by a Th1-type 
inﬂ  ammation, destruction of the alveolar septa, loss of 
elastic recoil, airspace enlargement and hence loss of gas 
diffusion capacity (Wright and Churg 2006). Chronic 
bronchitis affects the airways by airway inﬂ  ammation, 
goblet cell hyperplasia and mucus hypersecretion. In addi-
tion to decreased lung function, these patients experience 
chronic sputum production, coughing and often dyspnoea. 
Ciliated airway epithelium lining the airway lumen is 
impaired in its function due to the hypersecreted mucus, 
and in activation and damage by tobacco compounds. As 
a result, the ciliated epithelium may be partly replaced 
by other epithelial cell types like squamous and goblet 
cells, further contributing to the airway dysfunction. The 
inﬂ  ammatory phenotype in chronic bronchitis is neutro-
philic or eosinophilic. In eosinophilic chronic bronchi-
tis the sputum or bronchoalveolar lavage (BAL) ﬂ  uid 
presents more eosinophils whereas in neutrophilic airway 
inﬂ  ammation predominates the neutrophilic phenotype. 
The eosinophilic phenotype exhibits a higher reversible 
forced expiratory volume in 1 second (FEV1) as compared 
to the neutrophilic phenotype, and is more responsive to 
corticosteroid treatment (Chanez et al 1997; Pizzichini 
et al 1998; Brightling et al 2005). Small airways disease 
mainly affects the bronchioles featuring airway inﬂ  am-
mation and metaplasia of Clara cells.
Pathogenesis
The pathogenesis of COPD is not known yet. However, patho-
logical features of COPD include lung tissue and vascular 
remodeling, and pulmonary and systemic inflammation 
(Barnes et al 2003; Langen et al 2003; Hogg 2004; De Boer 
2005; Wright and Churg 2006; De Boer et al 2007). Clinical 
research in patients with established COPD showed inﬂ  amma-
tion with cells involved in innate immunity including macro-
phages, neutrophils, and T cells (predominantly CD8+, but less 
prominent in severe COPD) (Grashoff et al 1997; Di Stefano 
et al 2001; Hogg 2004; Barnes and Stockley 2005; De Boer 
2005). Some studies also showed higher lung tissue numbers 
of mast cells, and also eosinophils during exacerbations or 
in patients with COPD showing reversible lung function 
(Grashoff et al 1997; Papi et al 2000; Barnes and Stockley 
2005; De Boer 2005). Differences between the outcomes of 
studies may be due to inclusion criteria, numbers of participat-
ing patients, the COPD phenotype studied or the pulmonary 
location of sampled tissue. Recent studies also point to a link 
between the innate and acquired immune system. Studies with 
COPD patients demonstrated the presence of B-cell follicles in 
lung tissue (Gosman, Willemse et al 2006; van der Strate et al 
2006) while studies on smoke-exposed mice show a role for 
dendritic cells in the pathogenesis of emphysema (Bracke et al 
2006). A limited number of studies suggested an autoimmune 
component in emphysema (Agusti et al 2003). This suggestion 
was based on observations showing the presence of T cells 
(CD8+ and CD4+), B cell follicles in the airway walls, and 
clonal expansion of CD4+ T cells in lung tissue, the presence 
of anti-idiotypic antibodies with tobacco-like activity, and 
induction of emphysema in rats via a CD4+ and in mice via 
a CD8+ cell-speciﬁ  c mechanism (Saetta et al 1999; Koethe 
et al 2000; Sullivan et al 2005; Taraseviciene-Stewart et al 
2005; Gosman, Willemse et al 2006; van der Strate et al 2006; 
Maeno et al 2007).
Oxidants and proteinases
Mechanisms that may contribute to the pathogenesis involve 
disturbed oxidant-antioxidant and proteinase-antiproteinase 
balances. Lungs are continuously exposed to oxidants, either 
generated endogenously by metabolic reactions (eg, from 
mitochondrial electron transport during respiration or during 
activation of phagocytes) or exogenously, such as air pollutants 
or cigarette smoke. Tobacco smoke constitutes about 5000 
compounds and 1017 free radicals per puff, many of which 
are able to induce reactive oxygen or nitrogen species that can 
be inactivated by endogenous molecules like SOD, catalase, 
cytochrome P450, ﬂ  avanoids and glutathione. In patients with International Journal of COPD 2007:2(3) 207
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COPD this balance may be disturbed due to mutations in genes 
encoding these enzymes or enzymes related to these pathways 
(Langen et al 2003; Rahman and Adcock 2006). Production 
of reactive oxygen species (ROS) has been directly linked to 
oxidation of proteins, DNA, and lipids, which may cause direct 
lung injury or induce a variety of cellular responses, through 
the generation of secondary metabolic reactive species (Repine 
et al 1997). ROS may alter remodeling of extracellular matrix 
(ECM) and blood vessels, stimulate mucus secretion, inactivate 
antiproteases, cause apoptosis, and regulate cell proliferation 
(Rahman and MacNee 1996a, 1996b, 1999). Furthermore, 
increased levels of ROS have been implicated in initiating 
inﬂ  ammatory responses in the lungs through the activation of 
transcription factors such as nuclear factor-kappaB (NF-κB) 
and activator protein-1 (AP-1), signal transduction, chromatin 
remodeling and gene expression of pro-inﬂ  ammatory media-
tors (Rahman and MacNee 1998).
4-Hydroxy-2-nonenal (4-HNE) is a highly reactive and 
speciﬁ  c diffusible end-product of lipid peroxidation, and 
is found to induce the COX-2 genes in RAW264.7 cells 
(Kumagai et al 2004), thus reﬂ  ecting the potential role of 
4-HNE as perpetrator of inﬂ  ammation. Furthermore exog-
enous micromolar levels of 4-HNE increases the expression 
of several genes eg, heme oxygenase-1, collagen α1(I), and 
aldose reductase (Parola et al 1993; Basu-Modak et al 1996; 
Spycher et al 1997). Also 4-HNE has been reported to have 
chemotactic, cytotoxic and immunogenic properties both in 
vitro and in vivo (Schaur et al 1994; Steinerova et al 2001), 
and these effects were achieved in vitro with 4-HNE con-
centrations as low as 2.5 μM (Muller et al 1996). Data from 
the authors’ laboratories indicate increased 4-HNE-modiﬁ  ed 
protein levels in airway and alveolar epithelial cells, endothe-
lial cells and neutrophils in subjects with airway obstruction 
compared to subjects without airway obstruction (Rahman 
and MacNee 2000b; Rahman et al 2002). An important 
outcome of 4-HNE generation is its interaction with the 
important thiol antioxidant glutathione (GSH) (Tjalkens 
et al 1999). The conjugation of 4-HNE with GSH might be 
one of the important mechanism whereby a cell may lose its 
antioxidant pool leading to oxidative stress. Interestingly, 
increased formation of 4-HNE has also been reported to 
induce expression of glutamyl cysteine ligase (GCL) gene 
which increases synthesis of GSH. This might be an impor-
tant cellular antioxidant adaptation during oxidative stress. 
Inhibition of lipid peroxidation, speciﬁ  cally the pathways 
leading to the production of 4-HNE and F2-isoprostane, 
may therefore be important and novel targets for antioxidant 
therapy in inﬂ  ammation and injury in patients with COPD.
One of deleterious outcomes of oxidative stress is the 
remodeling of ECM leading to lung injury. ROS activate latent 
proforms of matrix metalloproteinase (MMP) (Lindholt et al 
2003), and antioxidant species decrease MMP expression and 
activation (Rajagopalan et al 1996). Cigarette smoke treatment 
of alveolar macrophages from subjects with COPD induced 
increased release of MMP-9 compared to that of non-smokers. 
MMP-9 has an ECM degrading activity, thus suggesting the 
role of oxidative components of cigarette smoke in increased 
elastolytic enzyme activity (Russell et al 2002). Increased 
proteolytic load due to MMP-9 has been attributed to increased 
neutrophil recruitment in the lungs that triggers degradation 
of ECM and basement membrane in the airways and lungs. 
Antioxidants N-acetylcysteine and pyrrolidine dithiocar-
bamate, and the NADPH oxidase inhibitors diphenylene 
iodonium chloride and apocynin decreased the production of 
MMP-2 and -9 in alveolar macrophages from surfactant pro-
tein D-deﬁ  cient mice (Yoshida et al 2001). However, a recent 
study showed that mice lacking gp91phox, a phagocyte-speciﬁ  c 
component of the NADPH oxidase, developed extensive, 
spontaneous emphysematous destruction of their peripheral 
air spaces (Kassim et al 2005). In addition, peritoneal macro-
phages from gp91phox-null mice had greater MMP-12 activity 
than macrophages from wild type mice (Kassim et al 2005). 
These ﬁ  ndings indicate that reactive intermediates provide a 
physiological mechanism to protect tissues from excessive 
macrophage-mediated damage during inﬂ  ammation. Factors 
other than oxidative stress, such as ozone and lipid peroxides 
also induce collagen I and MMP-1 gene expression (Choi et al 
1994). Other forms of oxidative stress derived from tert-butyl 
hydroperoxide and iron can also modify collagen synthesis, by 
a mechanism presumably involving redox sensor/receptor.
The proteinase-antiproteinase dysbalance is thought to 
be related to the increased proteolytic activity or protease 
expression observed in sputum, BAL ﬂ  uid or tissue of patients 
with COPD, and tissue remodeling or destruction as seen in 
emphysema (Barnes et al 2003; Hogg 2004). Several studies 
reported enhanced levels or gene mutations of MMPs like 
MMP-1, MMP-9 or MMP-12 associated with COPD and 
lung function decline (Joos et al 2002; Culpitt et al 2005; 
Demedts et al 2006), the presence of fragments of ECM 
proteins like elastin or collagen (Dillon et al 1992; Stone et al 
1995; Weathington et al 2006), and/or altered levels of ECM 
molecules in sputum, BAL ﬂ  uid or lung tissue of patients with 
COPD (Lang et al 1994; Dentener et al 2005; Kranenburg et al 
2006; Martin-Mosquero et al 2006). Extracellular matrix hyal-
uronan (HA) has a pro-inﬂ  ammatory role and HA levels were 
found to be increased in sputum of COPD patients (Dentener International Journal of COPD 2007:2(3) 208
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et al 2005). Two categories of COPD subjects have been identi-
ﬁ  ed: one group having high HA levels and the other having 
moderate levels. COPD subjects exhibiting higher HA levels 
had low FEV1 as compared to moderated and control categories. 
Increased breakdown and therefore increased HA levels were 
further correlated with an increased expression of hyaluroni-
dase 2 gene. Furthermore, increased HA breakdown has been 
associated with local inﬂ  ammation and severity of COPD. Yet, 
a recent study demonstrated that aerosolized HA limits airspace 
enlargement in a mouse model of cigarette smoke-induced 
pulmonary emphysema (Cantor et al 2005). In addition, treat-
ment with HA partially blocked LPS (1 ng/ml) induced TNFα 
release by blood cells from COPD patients (Dentener et al 
2006). Thus the high levels of HA in COPD subjects would be 
a consequence of degradation of ECM, which in turn can bind 
to lung elastic ﬁ  bers, thereby adaptively preventing their further 
degradation by protease (Cantor et al 1997, 2000). Targeted 
deletion of neutrophil elastase or MMP-12 protects from the 
development of cigarette smoke or gp91 deﬁ  ciency-induced 
emphysema (Hautamaki et al 1997; Shapiro et al 2003; Kassim 
et al 2005). Furthermore, the structural alterations in ECM pro-
teins may provoke an immune reaction, whereas degradation 
fragments generated during extensive tissue remodeling may 
lead to antigenic fragments also provoking an immune reac-
tion. More speciﬁ  cally, exposure to reactive oxygen or nitrogen 
intermediates or aldehydes present in smoke or produced by 
inﬂ  ammatory cells may lead to adduct formation of structural 
(lipo)proteins in the lung eg, as a result of lipid peroxidation 
or protein carbonyl formation (Rahman and Adcock 2006). In 
turn, this may result in the formation of neo-epitopes of ECM 
proteins (Kirkham et al 2004; Morquette et al 2006). The 
induction of neo-antigens upon tobacco smoke exposure may 
lead to speciﬁ  c B and T cell clones that provoke autoimmune 
reactions. Alternatively, during embryogenesis speciﬁ  c B and 
T cells are being selected and generated by peptide fragments 
of extracellular matrix components secreted by lung epithelial 
cells. At that moment, the immune system is tolerant to these 
peptides. Upon smoke exposure, these B and/or T cells may be 
activated causing the inﬂ  ammatory phenotype and speciﬁ  c lung 
parenchymal destruction as seen in emphysema. Some of the 
mechanisms are outlined in Figure 1. As COPD is detected in 
an advanced form only at later age, other models are needed to 
study these and other pathogenetic mechanisms of COPD.
Cytokines and chemokines
Inﬂ  ammation is one of the hallmarks of COPD. Inﬂ  amma-
tory cells are known to migrate to chemotactic gradients, or 
to express and produce pro- or anti-inﬂ  ammatory proteins, 
MMPs and other proteases, growth factors, antibacterial 
proteins like α-defensins, β-defensins and cathelicidins, 
and/or to degranulate by a plethora of molecules including 
cytokines, chemokines, growth factors, and arachidonic acid 
derivates (like prostaglandins, leukotrienes and thrombox-
anes) (De Boer 2002; Bals and Hiemstra 2006; Rahman and 
Adcock 2006; Rolin et al 2006). Classical cytokines include 
TNFα, interleukins (ILs) and interferons (IFNs). Chemokines 
can be subdivided into four subfamilies based on their struc-
tural homology around 4 cysteine residues: -C-, -CC-, -CXC-, 
and -CXXXC-, in which X substitutes for any amino acid. 
The major subfamilies are the -CXC- (or: α chemokines, 
and the -CC- chemokines (or: β-) chemokines) (De Boer 
2002). Gene expression of cytokines and chemokines is 
regulated by transcription factors including AP-1 and Fos, 
and signal transduction kinases like mitogen activated pro-
tein kinase (MAPK) p38, Jun kinase (JNK), and NF-κB, and 
are synthesized by both structural cells (such as ﬁ  broblasts, 
epithelial, endothelial, and muscle cells) and inﬂ  ammatory 
cells of the innate and the adaptive immune system. They 
act via speciﬁ  c membrane-bound receptors resulting in cell 
speciﬁ  c reactions. In patients with COPD, protein and/or 
mRNA levels of different cytokines and chemokines have 
been found to be altered compared with subjects without 
COPD (Table 1).
Among these, TNFα or TNFR levels, soluble IL-1 recep-
tor antagonist (sIL-1Ra), CCL2 (monocyte chemoattractant 
protein 1, MCP-1) and its receptor CCR2, CCL3 (macro-
phage inﬂ  ammatory protein 1α, MIP-1α) and CCL4 (MIP-
1β) and their receptor CCR5, CXCL8 (IL-8), and CXCL10 
(interferon-inducible protein 10, IP-10) can be discerned as 
pro-inﬂ  ammatory factors. In addition to the inﬂ  ammatory 
effects, recent studies provided more evidence that cytokines 
and chemokines are also involved in tissue remodeling apart 
from growth factors, pointing to cytokine-driven effects of 
inﬂ  ammatory cells on epithelial wound repair (De Boer et al 
2007) (Figure 1).
CCL2 is produced by a variety of cells including macro-
phages, endothelial and epithelial cells. It binds to CCR2, a 
receptor that is highly expressed on circulating blood DCs 
and monocytes, and thus primarily controls their recruitment 
from the blood vessels to the tissue. CCL2 is also involved 
in tissue remodelling. In vitro, CCL2 and its receptor CCR2 
were demonstrated to be directly involved in endothelial 
and lung epithelial cell proliferation, migration and wound 
closure (De Boer et al 2007). In addition, CCL2 was found 
to stimulate collagen synthesis in rat lung ﬁ  broblasts via a 
TGFβ1-dependent pathway, hence potentially contributing to International Journal of COPD 2007:2(3) 209
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a ﬁ  brogenetic remodelling as seen in COPD. In turn, TGFβ1 
was reported to induce CCL2 protein levels via downstream 
intracellular mechanisms including ROS, and MAPK p38 
and p42/44 in mesangial cells (Cheng et al 2005). Results 
from studies in mice and cell lines suggest that oxidative 
stress activates MAPK p42/44 and p38 which stimulates 
the expression of TNFα, IL-1β, CCL2 and CXCL10 (Nishi 
et al 2005; Guest et al 2006; Huang et al 2006; Loke et al 
2006). Oxidative stress led to an inﬂ  ux of macrophages and 
increased expression of proteins like NADPH oxidase, thio-
redoxin-1 and inducible nitric oxide synthase, via a CCR2-
mediated mechanism (Hayasaki et al 2006). These effects 
were inhibitable by antioxidants including N-acetylcysteine, 
ascorbic acid, quercetin or overexpression of SOD1, deletion 
of CCR2, or by inhibition of MAPK p42/44 or p38 (Nishi 
et al 2005; Guest et al 2006; Hayasaki et al 2006; Huang et al 
2006; Loke et al 2006). Hence the CCL2-CCR2-TGFβ axis 
may potentially contribute to tissue remodeling and inﬂ  am-
mation as seen in COPD.
CXCL1 (GROα) and CXCL8 are produced by both 
structural and inﬂ  ammatory cells including macrophages. 
Both bind to their receptor CXCR2 whereas CXCL8 binds 
also to CXCR1. Both receptors are expressed on neutrophils 
while CXCR2 is also expressed on other inﬂ  ammatory cells 
including a subset of CD8+ T cells, mast cells and macro-
phages. CXCL1 and CXCL8 are chemotactic and activate 
inﬂ  ammatory cells while CXCL8 also induces neutrophils 
to degranulate and causes an oxidative burst. Recent stud-
ies demonstrated that cigarette smoke-conditioned medium 
induces human monocytes or macrophages in vitro to 
release CXCL8 (Karimi et al 2006; Yang et al 2006). As 
inhibitors of Toll-like receptor (TLR)-4, NF-κB and IKK-2 
Figure 1 Simpliﬁ  ed summary of inﬂ  ammatory and remodeling mechanisms in the airways in COPD. Exposure to cigarette smoke in susceptible individuals leads to an abnormal 
inﬂ  ammation and tissue remodeling. This appears to be self-perpetuating and may be linked to infection. Tobacco smoke activates different cell types including macrophages, epithelial 
and smooth muscle cells to produce cytokines, growth factors or proteases. Reactive molecules in tobacco smoke stimulate airway macrophages to produce cytokines and reactive 
oxygen or nitrogen species. Activated macrophages and epithelial cells attract and activate inﬂ  ammatory cells including monocytes, macrophages, neutrophils and T cells. Alterna-
tively, reactive species may react with extracellular matrix (ECM), and lipid moieties causing cell damage, gene expression or oxidative stress in different cell types. Chemokines like 
CXCL-8 and CXCL-1 cause T cell and neutrophil chemotaxis and activation of neutrophils to degranulate proteases like elastase and MMPs, and produce reactive oxygen species 
like hydrogen peroxide or O2
•–. Radicals may activate proteases that in turn fragment ECM molecules and/or form ECM neo-epitopes. Oxygen radicals may also react with ECM 
leading to adducts or neo-epitopes. Altered or fragmented ECM molecules may stimulate inﬂ  ammation and auto-immune-like reactions. Tobacco smoke may also activate smooth 
muscle cells and ﬁ  broblasts to produce pro-inﬂ  ammatory cytokines and growth factors (GF) like VEGF, leading to Th1-mediated inﬂ  ammation and vascular remodelling. Loss of 
epithelial cells due to direct toxicity of smoke, TNFα-induced apoptosis, or degradation of ECM, induces a repair process. Growth factors like EGF, FGF, TGFβ1 and VEGF stimulate 
tissue repair and vascular remodelling seen in COPD. Epithelial remodelling (squamous or mucous metaplasia, hyperplasia) may be due to excessive growth factor production or by 
TNFα resulting in a loss of lung clearance function and mucus hyperproduction.   A-HNE, 4-hydroxy-2-nonenal; ROS, reactive oxygen species; RNS, reactive nitrogen species.
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impaired the CXCL8 expression this points to a TLR4 and 
NF-κB dependent mechanism. In addition, CXCL8 release 
was signiﬁ  cantly inhibited by the anti-oxidant glutathione 
pointing to a regulatory effect of the chemokine expression 
by the redox status of the cells (Yang et al 2006). In contrast 
to monocytes, cigarette smoke conditioned medium did not 
affect CXCL8 or IL-6 expression nor NF-κB activation in 
human lung epithelial cells in vitro (Moodie et al 2004). 
This suggests that oxidants exert differential effects on NF-
κB signalling and chemokine expression depending on the 
cell type, and that inﬂ  ammatory cells produce CXCL8 upon 
oxidant exposure. The study showed that also epithelial cells 
express CXCR2 suggesting a role for CXCL8/CXCR2 in 
wound repair (De Boer 2002). In vivo, impaired CXCR2 
expression in mice resulted in delayed skin wound repair 
as compared to wild type mice, which cannot be restored 
by exogenous CXCL8 (Devalaraja et al 2000; Milatovic 
et al 2003). In contrast, topical application of CXCL1 or 
CXCL8 stimulated human skin wound repair in chimeric 
mice (Rennekampff et al 1997, 2000), and stimulated human 
colon, skin and lung epithelial proliferation and/or migra-
tion in vitro (De Boer et al 2007). Inhibition of CXCL8 
or CXCL1 signaling or expression as a treatment target 
in COPD may hence inhibit inﬂ  ammatory cell activation 
and tissue degradation, but may potentially delay wound 
repair in COPD.
Cigarette smoke has been shown in vivo to be a cause of 
increased adherence of leukocytes to vascular endothelium 
(Noguera et al 1998). Shen and co-workers (1996) have 
shown that cigarette smoke condensate induces the expres-
sion of a subset of cell adhesion molecules, such as intercel-
lular adhesion molecule (ICAM-1), endothelial leukocyte 
adhesion molecule 1 (ELAM-1), and vascular cell adhesion 
molecule (VCAM-1) in human umbilical vascular endothelial 
cells associated with an increase in the binding activity of 
NF-κB suggesting the increased transendothelial migration 
of monocytes by cigarette smoking. The release of proin-
ﬂ  ammatory mediators, such as IL-1β and soluble ICAM-1, 
was increased by cigarette smoke exposure in bronchial 
epithelial cells cultured from biopsy materials obtained from 
patients with COPD compared to smokers (Rusznak et al 
2000). Moreover, Scott and coworkers (2000) demonstrated 
a clear dose-dependent relationship between smoke intake 
and sICAM-1 concentrations and sICAM-1 concentrations 
substantially reduced in those who stopped smoking for a 
year but remained elevated in continuing smokers. These 
results suggest that patients with COPD have a greater sus-
ceptibility to the effects of cigarette smoke.
Table 1 Molecules involved in inﬂ  ammation in COPD
Product Type  Compartment  Level  in  COPD
TNFα  mRNA, protein  serum, sputum, leg muscle  higher (COPD)
  gene polymorphism  blood  Asian: yes;   
    Caucasian:  no
TNFR1 protein sputum  higher  (COPD)
TNFR2 protein serum  higher  (COPD)
CCL2  mRNA, protein  sputum, BAL, lung tissue, BEC  higher (COPD)
CCR2  mRNA, protein  lung tissue, BEC  higher (COPD)
CXCL1  protein  sputum, lung tissue  higher (COPD)
CXCL8  mRNA, protein  serum, sputum, BAL, lung tissue  higher (COPD)
CXCR2  mRNA, protein  BAL, PBL  higher (COPD)
TGFβ1  mRNA, protein  lung tissue, BEC  higher (COPD)
  protein  lung tissue  lower (emph)
  gene polymorphism  blood  yes (COPD)
TGFβR1  protein  lung tissue  lower (emph)
TGFβR2  protein  lung tissue (arteries)  higher (COPD)
VEGF  protein  sputum, lung tissue  lower (emph)
    higher  (COPD)
VEGFR2  protein  lung tissue  lower (emph)
    higher  (COPD)
4HNE  protein adducts  lung tissue  higher (COPD)
NF-κB protein  lung  tissue  higher  (COPD)
HDAC2  mRNA, protein  lung tissue  lower (COPD)
HDAC5  mRNA  lung tissue  lower (COPD)
HDAC8  mRNA  lung tissue  lower (COPD)
Abbreviations: BAL, bronchoalveolar lavage; BEC, bronchial epithelial cells; emph, emphysema; PBL, peripheral blood lymphocytes.International Journal of COPD 2007:2(3) 211
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Growth factors: VEGF and TGFβ1
Growth factors can be divided into different superfamilies 
based on structural and functional homology. These families 
include vascular endothelial growth factor (VEGF), TGF-β, 
epidermal growth factor (EGF)-like growth factors, ﬁ  broblast 
growth factor (FGF) and insulin-like growth factor (IGF) 
(De Boer et al 2007). With regard to COPD several studies 
suggest the involvement of these families in either pulmonary 
inﬂ  ammation like for VEGF and TGFβ1 (De Boer et al 1998; 
Takizawa et al 2001; Postma and Timens 2006), vascular or 
tissue remodeling like for EGF-like growth factors, FGFs 
and VEGFs (Kranenburg et al 2002, 2005; De Boer et al 
2006; Postma and Timens 2006), or oxidative stress as with 
TGFβ1 or FGF-7 (Rahman et al 2000; Rahman et al 2002; 
Ray et al 2003) (Table 1). A review on growth factors as a 
potential target for drug therapy is presented elsewhere (De 
Boer et al 2007).
VEGF receptor impairment, VEGF gene deletion or 
generation of antibodies against VEGF receptors all cause 
airspace enlargement in rodents without airway inﬂ  ammation 
(Kasahara et al 2000). In addition, in murine models tobacco 
smoke exposure leads to decreased expression of VEGF and 
VEGF receptors as well as emphysematous lesions, as has 
also been observed in smokers with emphysema. Further-
more, blockade of VEGF receptors was shown to induce 
oxidative stress and alveolar cell apoptosis that was inhibited 
by exogenous administration of the SOD mimetic M40419 
(Tuder et al 2003). These data link oxidative stress with 
development of emphysema and abrogated VEGF signaling 
rather than alveolar damage induced by inﬂ  ammation alone. 
Tuder and coworkers proposed a disturbed balance between 
oxidative stress, proteinases, antiproteinases and apoptosis, 
and lung inﬂ  ammation as a non-speciﬁ  c reaction secondary 
to alveolar tissue damage (Tuder et al 2006). However, these 
data may not be applied to COPD as a whole as VEGF and 
VEGFR expression was observed to be enhanced in relation 
to vascular remodeling in non-emphysematous patients mak-
ing these patients less eligible for VEGF therapy (Kranenburg 
et al 2005; De Boer et al 2007).
TGFβ1 has been associated with COPD either as a 
result of oxidative stress or an imbalance in proteinases 
and antiproteinases, but may also be related to an aberrant 
repair process and hence progression of COPD (Postma 
and Timens 2006; Rahman and Adcock 2006). TGFβ1 
expression was demonstrated to be enhanced in patients 
with COPD (De Boer et al 1998) but decreased in patients 
with emphysema (Zandvoort et al 2006). The expression of 
intracellular inhibitory signaling proteins of TGFβ1, Smad6 
and Smad7, was observed to be decreased both in bronchial 
and alveolar tissue from patients with COPD, whereas in 
expression of stimulatory Smad molecules including Smad3 
was unaltered (Springer et al 2004; Zandvoort et al 2006). 
Smad7 is involved in the regulation of expression of inﬂ  am-
matory proteins. In vivo wound healing study with mice 
demonstrated that overexpression of Smad7 inhibits TGFβ1, 
CCL2, VEGF, MMP-9 and TIMP-2 protein and mRNA 
expression (Saika et al 2005). Reducing overexpression of 
Smad7 in patients with inﬂ  ammatory bowel disease (IBD) 
using antisense Smad7 oligonucleotides caused a decreased 
production of proinﬂ  ammatory cytokines IFNγ and TNFα 
upon treatment of intestinal tissue explants and cells with 
TGFβ1 (Monteleone et al 2001). With regard to COPD, it 
is not known whether Smad7 downregulation is intrinsic 
or due to inﬂ  ammation, oxidative stress, or other factors, 
and what the consequences are of differential expression 
of TGFβ1 in patients with COPD or emphysema alone. 
An alternative hypothesis is that tobacco smoke exposure 
causes excessive growth factor production resulting in tissue 
remodeling, independent of inﬂ  ammation. Recent data from 
a murine study (Churg et al 2006) provided support for this 
idea. Their study demonstrated that short-term smoke expo-
sure for 2 hours stimulated early growth factor expression 
including TGFβ1 and type 1 procollagen synthesis before 
the onset of inﬂ  ammation. Upon chronic smoke exposure 
for up to 6 months proﬁ  brotic growth factor expression 
continued as well as tissue remodeling characterized by 
enhanced collagen deposition, while other studies showed 
the development of airway inﬂ  ammation and emphysema in 
rodents in this period. Taken together, the balance between 
TGFβ1 and Smad7 expression in pulmonary cells of patients 
with COPD seems to be delicate and may affect tissue 
remodeling and inﬂ  ammation differently depending on the 
COPD phenotype. Targeting TGFβ1 as a therapy in COPD 
requires more studies on the precise role of these factors in 
the pathogenesis of COPD.
Figure 1 outlines brieﬂ  y the proposed remodeling and 
inflammatory mechanisms in COPD, whereas Figure 2 
summarizes potential intervention strategies. Based on this, 
speciﬁ  c anti-inﬂ  ammatory therapies are being developed for 
COPD (De Boer 2005).
Current therapies
Therapies for COPD are mainly based on anti-inﬂ  ammatory 
drugs for treating asthma, including corticosteroids 
or theophylline with or without bronchodilators like 
β2-agonists. Some studies reported reduction of the number International Journal of COPD 2007:2(3) 212
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of exacerbations, improved quality of life and an decline 
in FEV1 after short- or long-term treatment with inhaled 
corticosteroids, or no effect on lung function (Gartlehner 
et al 2006). Though some recent studies using higher doses 
or longer duration of treatment showed reduced airway 
inﬂ  ammation, steroid treatment of patients with COPD 
is rather ineffective in reducing the decline in lung func-
tion (Barnes and Stockley 2005; Gan et al 2005). Adverse 
effects of steroids include increased risk of hip fractures 
and osteoporosis, skin bruising and candidiasis (Gartlehner 
et al 2006), and the airway remodeling is not positively 
affected by the current treatment. Anti-oxidant therapy 
by mucolytics such as N-acetylcysteine is also being used 
as a treatment reducing acute exacerbation frequency, but 
generally fails to reduce airway inﬂ  ammation or decline 
in lung function (Poole and Black 2006; Sadowska et al 
2007). Adverse effects of these mucolytic agents are rarely 
seen. The ﬁ  nal part of this review focuses on the recent 
developments and advances in potential anti-oxidant and 
anti-cytokine treatment (Table 2).
Development of antioxidant agents 
and anti-inﬂ  ammatory therapies
Development of antioxidant therapies
Systemic and local antioxidant capacity
and antioxidant vitamins
Smoking and exacerbations of COPD result in decreased 
antioxidant capacity in plasma in association with depleted 
protein sulphydryls in the plasma (Rahman et al 1996, 1997; 
Corradi et al 2003). The decrease in antioxidant capacity 
Figure 2 Emerging anti-inﬂ  ammatory therapy. The chronic, persistent inﬂ  ammation and tissue remodeling that ensues in COPD is thought to be responsible for both the 
symptoms of disease and also the progressive decline in lung function. The loss of airway function appears to be related to the destruction of alveoli resulting in a loss of 
elasticity linked to increased protease activity in emphysema, and/or obstruction and ﬁ  brosis of the (small) airways as a result of inﬂ  ammation and mucus hypersecretion 
in chronic bronchitis. Emerging anti-inﬂ  ammatory therapies under clinical investigation attack this chronic pulmonary inﬂ  ammation via several strategies. Signaling pathway 
inhibitors such as PDE4 inhibitors, MAPK p38 inhibitors, NF-κB signaling inhibitors and PI3K inhibitors are in development. Reduction of pleiotropic inﬂ  ammatory cytokines 
such as TNFα using monoclonal antibodies that target the ligands, or soluble receptors that bind and inactivate TNFα may also reduce the inﬂ  ammatory burden in the lung. 
Targeting chemokines like CCL2 and CXCL8 may reduce the inﬂ  ux of inﬂ  ammatory cells into the lungs from the circulation by reducing the chemotactic gradient. Inhibition 
of protease activity in the lung may attenuate lung tissue damage and reduces the numbers of lung neutrophils. Increased HDAC2 expression restores the sensitivity for 
steroids in the treatment of COPD. Reducing the severity of inﬂ  ammation and tissue remodeling may improve lung function and slow the progression of COPD.
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in smokers occurs transiently during smoking and resolves 
rapidly after smoking cessation. In exacerbations of COPD, 
however, antioxidant capacity remains low for several days 
after the onset of the exacerbation, tending to return towards 
normal values at the time of recovery from the exacerbation 
(Rahman et al 1997). The depletion of antioxidant capacity 
could in part be explained by the increased release of ROS 
from peripheral blood neutrophils, as shown by a signiﬁ  cant 
negative correlation between neutrophil superoxide anion 
release and plasma antioxidant capacity (Rahman et al 1996). 
Thus there is clear evidence that oxidants in cigarette smoke 
markedly decreases plasma antioxidants, which may play an 
important role in the pathogenesis of COPD. Furthermore, 
it is possible that inter-individual differences in antioxidant 
capacity may contribute to the differences in susceptibility 
to cigarette-smoke induced COPD. Thus, it is imperative to 
propose the rationale for antioxidant therapy ameliorating the 
increased oxidative stress and consequently the inﬂ  ammatory 
response in COPD.
Depletion of total antioxidant capacity in smokers is 
associated with decreased levels of major plasma antioxi-
dants in smokers (Petruzzelli et al 1990; Bridges et al 1993; 
van Antwerpen et al 1993; Mezzetti et al 1995; Rahman and 
MacNee 1996a). These studies show depletion of ascorbic 
acid, vitamin E, β-carotene and selenium in the serum of 
chronic smokers and in patients with COPD (Petruzzelli 
Table 2 Examples of potential cytokine and oxidant antagonist drugs for COPD
Target  Compound  Mechanism  Status for disease
TNFα
Inﬂ  iximab  chimeric IgG1 TNFα antibody  scavenging TNFα  A (2) RA, CD, psor. (COPD, SA)
Etanercept  hu TNFR2-Fc IgG1 fusion protein  scavenging TNFα  A (2) RA, psor. (SA)
Adalumimab hu  IgG1  TNFα antibody  scavenging TNFα A  RA
PEG-sTNFR1  PEGylated hu TNFR1  scavenging TNFα 2  RA
Afelimomab murine  TNFα antibody  scavenging TNFα 3  sepsis
ISIS104838 antisense  TNFα oligonucleotide  impaired TNFα translation  2  RA
CCL2/CCR2
MLN1202  humanized CCR2 antibody  inhibits CCL2 binding  2  ART, MS
CCX915 small  molecule  CCR2  antagonist  1  MS
ABN912  CCL2 antibody  scavenging CCL2  1,2  COPD, RA
INCB3284  small molecule  CCR2 antagonist  2  RA
CXCL1/CXCL8/CXCR1/CXCR2
SB656933 small  molecule  CXCR2  antagonist  preclinical
AZD8309  pyrimidine derivate  CXCR2 antagonist  1,2  COPD, RA
SCH527123  cyclobutenedione derivate  CXCR2 antagonist  preclinical
  Thiazolpyrimidine derivate  CXCR2 antagonist  experimental
  Imidazolylpyrimidine derivate  CXCR2 antagonist  experimental
PDE4 inhibitors
Roﬂ  umilast  methoxy-N-pyridyl-benzamide derivate  inhibition of PDE4  3  COPD, asthma
Cilomilast  cyano-cyclohexanecarboxylate derivate  inhibition of PDE4  3  COPD
Oglemilast    inhibition of PDE4  2  COPD
Tetomilast  thiazole derivate  inhibition of PDE4  2 (3)  COPD (IBD)
SB256066   inhaled PDE4 inhibitor  1  COPD, asthma, AR
Signal transduction
 antisense  NFκB oligonucleotide  impaired NFκB translation  experimental
BMS345541  imidazoquinoxaline derivate  IKK-1 and -2 inhibitor  preclinical
SPC839  quinazoline derivate  IKK-2 inhibitor  experimental
RWJ67657  pyridylimidazolbutyn-1-ol  JNK2, MAPK p38 inhibitor  1  RA, CD, AR, psor
SB856553    oral MAPK p38 inhibitor  1  COPD, RA, ART
SB681323    oral MAPK p38 inhibitor  1,2  COPD, RA, ART
BIRB796  diaryl urea derivate  MAPK p38 inhibitor  3  inﬂ  amm, RA, CD
SD-282  indole-5-carboxamide  oral MAPK p38α inhibitor  preclinical
Anti-oxidants
M40403 Mn-pentaazatetracyclohexacosatriene  soluble  SOD  mimetic  2/3  pain
M40419  small molecule  soluble SOD mimetic  1  pain
Status indicates the experimental, preclinical or clinical trial phase for the mentioned disease.
Abbreviations: A, approved by US Federal drug administration or European union; AR, allergic rhinitis; ART, artherosclerosis; CD, Crohn’s diseases; IBD, inﬂ  ammatory 
bowel disease; inﬂ  amm, inﬂ  ammation; MS, multiple sclerosis; psor, psoriasis; RA, rheumatoid arthritis; SA, severe asthma.International Journal of COPD 2007:2(3) 214
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et al 1990; Bridges et al 1993; van Antwerpen et al 1993; 
Mezzetti et al 1995; Tug et al 2004). Moreover, decreased 
vitamin E and vitamin C levels were reported in leukocytes 
and BAL ﬂ  uids from smokers. Ascorbate appears to be a 
particularly important antioxidant in the plasma. Cigarette 
smoke-induced lipid peroxidation of plasma in vitro is 
decreased by ascorbate (Cross et al 1994). Reduced levels 
of vitamin E and a marginal increase in vitamin C in the 
BAL ﬂ  uid of smokers, compared to nonsmokers have been 
shown (Rahman and MacNee 1996a). Similarly, alveolar 
macrophages from smokers have both increased levels of 
ascorbic acid and augmented uptake of ascorbate, suggesting 
that these cells are trying to redress their antioxidant balance 
(Rahman and MacNee 1996a).
Dietary antioxidants supplementation is one of the 
simplest approaches to boost antioxidant defense systems. 
Supplementation of vitamin C, vitamin E and β-carotene has 
been attempted in cigarette smokers and patients with COPD 
(Cross et al 1993; Rautalahti et al 1997; Steinberg and Chait 
1998; Aghdassi et al 1999; Habib et al 1999; Lykkesfeldt 
et al 2000; Uneri et al 2006). In the general population there 
is a positive association between dietary intake of antioxidant 
vitamins and lung function. Epidemiological studies have 
demonstrated negative associations of dietary antioxidant 
intake with pulmonary function and with obstructive airway 
disease (Grievink et al 1998). Britton and co-workers (Britton 
et al 1995) showed a positive association between dietary 
intake of the antioxidant vitamin E and lung function in a 
population of 2,633 subjects, supporting the hypothesis that 
this antioxidant may have a role in protecting against the 
development of COPD. Another study has suggested that 
antioxidant levels in the diet could be a possible explanation 
for differences in COPD mortality in different populations 
(Sargeant et al 2000). Dietary polyunsaturated fatty acids 
may also protect cigarette smokers against the development 
of COPD (Shahar et al 1999). These studies support the 
concept that dietary antioxidant supplementation including 
polyphenols may be a possible therapy to prevent or inhibit 
the oxidative stress and inﬂ  ammatory responses, which are 
key features in the development of COPD. However, robust 
clinical trials using dietary antioxidant vitamins and poly-
phenols are urgently needed to address the beneﬁ  cial effects 
of these antioxidants in COPD.
Directly increasing lung antioxidant capacity
The development and progress of COPD is associated with 
increased oxidative stress or decreased antioxidant resources 
(Boots et al 2003). The most direct way to redress the oxidant/
antioxidant imbalance in COPD would be to increase the pulmo-
nary capacity by antioxidants (Table 3). A variety of means by 
which to do this have been attempted with varying success.
Glutathione and its biosynthesis
The thiol antioxidant glutathione (GSH) is concentrated 
in epithelial lining ﬂ  uid compared with plasma and has an 
important protective role in the airspaces and intracellularly 
in epithelial cells. Several studies have suggested that GSH 
homeostasis may play a central role in the maintenance of the 
integrity of the lung airspace epithelial barrier. Decreasing 
the levels of GSH in epithelial cells leads to loss of barrier 
function and increased permeability (Morrison et al 1999). 
Human studies have shown elevated levels of glutathione 
in epithelial lining ﬂ  uid in chronic cigarette smokers com-
pared with non-smokers (Morrison et al 1999). However, 
this increase is not present immediately after acute cigarette 
smoking (Morrison et al 1999). The two-fold increase in 
BALF GSH in chronic smokers may not be sufﬁ  cient to 
deal with the excessive oxidant burden during smoking, 
when acute depletion of GSH may occur (Harju et al 2002). 
In addition, the immunoreactivity of γ-glutamylcysteine 
synthetase (γ-GCS; now called as glutmate cysteine ligase, 
GCL), the rate limiting enzyme in GSH synthesis, was 
decreased in the airways of smokers compared to non-
smokers, suggesting that cigarette smoke predisposes lung 
cells to ongoing oxidant stress (Harju et al 2002). Neurohr 
and colleagues recently showed that decreased GSH levels 
in BALF cells of chronic smokers were associated with a 
decreased expression of γ-GCS/GCL-light subunit without 
a change in γ-GCS/GCL-heavy subunit expression (Neurohr 
et al 2003). Increasing the activity of γ-GCS/GCL, would be 
expected to increase cellular GSH levels. The induction of 
γ-GCS/GCL by molecular means to increase cellular GSH 
levels or γ-GCS/GCL gene therapy also holds great promise 
in protection against chronic inﬂ  ammation and oxidant-
mediated injury in COPD.
Direct increase of lung cellular levels of GSH would be a 
logical approach to enhance the antioxidant potential in the 
treatment of COPD. In fact, extracellular augmentation of 
GSH has been tried through intravenous administration of 
GSH, oral ingestion of GSH, and aerosol inhalation of nebu-
lized GSH in an attempt to reduce inﬂ  ammation in various 
lung diseases (Rahman and MacNee 1999, 2000a, 2000b). 
However, these routes of administration lead to undesirable 
effects suggesting that direct GSH therapy may not be an 
appropriate way of increasing GSH levels in lung epithe-
lial lining ﬂ  uid and cells in COPD. The bioavailability of International Journal of COPD 2007:2(3) 215
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GSH, pH, osmolility in the inﬂ  ammatory micro-environment 
and the resultant formation of toxic products (GSSG and 
GSH-adducts) are further challenges for direct GSH admin-
istration. Alternative formulations may address bioavail-
ability, such as liposomal delivery, but at present it seems 
that direct administration of GSH will not be successful in 
treating COPD.
N-acetyl-L-cysteine (NAC)
NAC, a cysteine-donating reducing compound, acts as a 
cellular precursor of GSH and becomes de-acetylated in the 
gut to cysteine following oral administration (Cotgreave 
1997; Repine et al 1997). NAC may also reduce cystine to 
cysteine, which is an important mechanism for intracellular 
GSH elevation in vivo in lungs. It reduces disulphide bonds 
(a property of a good reducing agent), but also has the poten-
tial to interact directly with oxidants. NAC is also used as a 
mucolytic agent, to reduce mucus viscosity and to improve 
mucociliary clearance.
Pharmacological administration of NAC has been used in 
an attempt to enhance lung GSH in patients with COPD with 
varying success (Rasmussen and Glennow 1988; Bridgeman 
et al 1994). Schooten et al have reported that in a randomized, 
double-blind, placebo-controlled Phase II trial, a six month oral 
dose of 600 mg twice a day (b.i.d), reduced various plasma and 
BAL ﬂ  uid oxidative biomarkers in smokers (Van Schooten et al 
2002). Similarly, it has been shown that treatment with NAC 
600 mg once daily for 12 months also reduced the concentra-
tion of H2O2 in EBC compared to placebo in stable COPD 
patients (Kasielski and Nowak 2001). A more recent clinical 
Table 3 Examples of antioxidant compounds currently in clinical trials for COPD treatment
Name/Company  Antioxidant  Disease and phase of clinical trials  Mechanism of action
AstraZeneca  N-Acetyl-L-cysteine –   Bronchiectasis; COPD; Cystic ﬁ  brosis  Antioxidant
  AstraZeneca  Highest phase trial is launched
 (MucomystÂ®;  AstraZeneca)
Zambon (Italy)  N-acetyl-L-cysteine  Pulmonary ﬁ  brosis, COPD   Reducing agent; Oxygen 
  (Fluimucil; NAC; NSC-11118)  Highest phase trial is launched  radical formation
     antagonist
Galephar; Cystic Fibrosis   Nacystelyn  COPD, Cystic ﬁ  brosis Phase II trial  Antioxidant; Mucolytic
Foundation Therapeutics;
SMB Laboratories
Refarmed  Erdosteine  Bronchitis; Cough; Cystic ﬁ  brosis  Mucolytic agent; 
    Highest phase trial is launched  Antioxidant agent
Nattermann Ebselen  Asthma;  Atherosclerosis;  Antioxidant;  Glutathione
    Myocardial ischaemia Phase I trial  peroxidase stimulants
Redox Bio Science Inc  Recombinant human thioredoxin   Lung injury; ARDS, COPD  Thioredoxin stimulator; 
    Clinical studies are underway  Antioxidant agent
OXIS International  Glutathione peroxidase mimetics  Inﬂ  ammation, COPD Preclinical  Antioxidant
 –  Alteon
 (Organoselenium  compounds)
Sami Labs  Curcumin C3 Complex Curcumin  Cystic ﬁ  brosis, COPD, Cancer  Antioxidant and
    Highest phase trial is launched  anti-inﬂ  ammatory
Royalmount Pharma  Resveratrol and its analogs  Infection, COPD, Cancer Phase II  Anti-inﬂ  ammatory;
     Antioxidant  agent;
     Anti-cancer,
      Free radical scavenger
US Department of Health  Tempol (Spin trap)  Reperfusion injury; Inﬂ  ammation;  Apoptosis stimulator;
and Human Services    Cancer; ARDS, COPD Preclinical  Free radical scavenger;
     Anti-inﬂ  ammatory;
     Antioxidant  agent
CereMedix  CereMedixResearch programme:  COPD Preclinical  Antioxidant
 COPD  therapy
Aeolus Pharmaceuticals  Catalytic antioxidants  Reperfusion injury, Asthma, COPD,  Free radical scavenger;
Inc Corp  AEOL-10113(AEOL-10112;  Cancer, ARDS No development on  Antioxidant agent
 AEOL-10123)  trials  reported
Savient Pharmaceuticals Inc  OxSODrol  Asthma, COPD, ARDS  Superoxide dismutase 
  (Superoxide dismutase)  No development on trials reported  stimulator; Antioxidant
     agent
ARDS: acute respiratory distress syndromeInternational Journal of COPD 2007:2(3) 216
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trial also proves that oral administration of NAC 600 mg b.i.d. 
for 2 months rapidly reduces the oxidant burden in airways of 
stable COPD patients (De Benedetto et al 2005). This reduc-
tion in oxidative biomarkers results in clinical beneﬁ  t such as 
reduction in bronchial hypersecretion, in addition to decline 
in FEV1 and in exacerbations (Stey et al 2000). Orally dosed 
NAC has been shown to increase phagocytic activity of BAL 
macrophages from healthy smokers, but similar results were 
not seen in COPD patients, possibly due to active concentra-
tions of NAC not reaching the lung, as in vitro analysis of cells 
support an induction of phagocytosis by NAC. It has also been 
reported recently that orally dosed NAC increased the quadri-
ceps endurance time of severe COPD patients (Koechlin et al 
2004), thus suggesting that NAC administration may have ben-
eﬁ  cial effects on the systemic oxidative stress associated with 
COPD. However, a multi-centre study using NAC delivered 
by metered dose inhalers in patients with chronic cough failed 
to show a positive effect on well being, sensation of dyspnoea, 
cough or lung function (Dueholm et al 1992).
Whilst there is a body of evidence that the administration 
of NAC provides beneﬁ  t for COPD patients, it is not clear 
whether this represents a maintenance therapy (Decramer 
et al 2001, 2005). A phase III multicentre Bronchitis 
Randomized on NAC Cost-Utility Study (BRONCUS) 
has recently been completed, with the aim of addressing 
this question and determining whether the effectiveness of 
NAC as an “antioxidant” results in an alteration in the rate 
of decline in FEV1, exacerbation rate and quality of life in 
patients with moderate to severe COPD and hence support 
NAC administration as a maintenance therapy for COPD 
(Gerrits et al 2003; Dekhuijzen 2004). The results of the 
phase III BRONCUS trials showed no effect on decline 
in FEV1 but a reduction in hyperinﬂ  ation in patients with 
severe COPD and exacerbation rate in patients who are 
not treated with inhaled glucocorticoids (Decramer et al 
2001, 2005).
N-acystelyn (NAL)
NAL is a lysine salt of N-acetyl-L-cysteine, and is a 
mucolytic and antioxidant (reducing) thiol compound. The 
advantage of NAL over NAC is that it has a neutral pH in 
solution, whereas NAC is acidic. NAL can be aerosolized 
into the lung without causing signiﬁ  cant side effects (Gillis-
sen et al 1997). Gillissen and co-workers compared the effect 
of NAL and NAC and found that both drugs enhance intra-
cellular glutathione in alveolar epithelial cells and inhibited 
hydrogen peroxide and O2
• − released from human blood-
derived polymorphonuclear cells (PMN) from smokers 
with COPD (Gillissen et al 1997). NAL also inhibited ROS 
generation induced by serum-opsonised zymosan by human 
neutrophils. This inhibitory response was comparable to the 
effects of NAC (Gillissen et al 1997). Antonicelli and col-
leagues have shown that NAL inhibited oxidant-mediated 
CXCL8 release in alveolar epithelial A549 cells suggesting 
an anti-inﬂ  ammatory effect of NAL (Antonicelli et al 2002). 
Therefore, NAL may represent an interesting alternative 
approach to augment the antioxidant screen and thereby 
inhibiting inﬂ  ammatory responses in the lungs and has the 
advantage over other antioxidant agents in that it may be 
administered by inhalation. The clinical trials using NAL 
in the treatment of COPD are in progress.
N-isobutyrylcysteine (NIC)
Because NAC becomes hydrolyzed in biological systems, 
the measured bioavailability of the drug is low. Thus, it 
was speculated that a drug might be synthesized that pos-
sessed greater bioavailability than NAC, and could be 
used as a more effective treatment for chronic bronchitis. 
N-isobutyrylcysteine (NIC) is a NAC-like thiol compound 
that does not undergo effective ﬁ  rst-pass hydrolysis and 
hence has a higher oral bioavailability than NAC (Ekberg-
Jansson et al 1999). The oral bioavailability can be as high 
as 80%, dependent on food intake. However, when evaluated 
as a therapy for exacerbations of chronic bronchitis, NIC 
performed no better than placebo drugs, and not as well as 
NAC (Gillissen et al 1997). Furthermore, a study of NIC also 
failed to reduce exacerbation rates in patients with COPD 
(Ekberg-Jansson et al 1999).
Erdosteine
Erdosteine is a new thiol compound that also acts as an 
anti-oxidant, but in addition has mucoactive properties 
and reduces bacterial adhesiveness. In the “Equalife” ran-
domized placebo controlled clinical study, erdosteine was 
dosed orally 300 mg twice a day (b.i.d) for a period of 8 
months (Moretti et al 2004). Patients receiving erdosteine 
had signiﬁ  cantly fewer exacerbations and spent less days 
in hospital than the placebo group. Moreover, patients 
receiving erdosteine showed no reduction in lung function 
over this period and showed a signiﬁ  cant improvement in 
health related quality of life. It is not clear whether this 
clinical beneﬁ  t is due to antioxidant effects of erdosteine. 
The mucolytic effect of erdosteine is perhaps due to the 
presence of a sulphydryl group. It may be possible that 
erdosteine may reduce bacterial colonization through a 
direct effect on adhesion.International Journal of COPD 2007:2(3) 217
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Procysteine
Procysteine (L-2-oxothiazolidine-4-carboxylate), is a cyste-
ine donating compound which increases the cysteine levels 
of the cells and has a greater bioavailability than NAC. 
This thiol compound is well tolerated is has been shown to 
increase mitochondrial levels of GSH in alveolar type II cells 
(Guidot and Brown 2000). Glutathione esters, particularly 
GSH monoethyl esters can increase the GSH levels of the 
cells by cleavage of ester bond (an ethyl group esteriﬁ  ed to 
glycine). GSH esters have been shown to increase GSH levels 
in the lungs of rats, however, this compound can be cytotoxic 
and variation in the uptake levels of GSH has been shown in 
various cellular models (Butterworth et al 1993).
Antioxidant enzyme mimetics and spin traps
Increased activity of antioxidant enzymes (superoxide dis-
mutase and catalase) in alveolar macrophages from young 
smokers have been reported (McCusker and Hoidal 1990). 
However, Kondo and co-workers (Kondo et al 1994) found that 
the increased superoxide generation by alveolar macrophages 
in elderly smokers was associated with decreased antioxidant 
enzyme activities when compared with non-smokers. The 
activities of CuZnSOD, glutathione-S-transferase and gluta-
thione peroxidase (GP) are all decreased in alveolar macro-
phages from elderly smokers (Gilks et al 1998).
The activities of SOD and glutathione peroxidase have 
been shown to be higher in the lungs of rats exposed to 
cigarette smoke. McCusker and Hoidal (1990) have also 
demonstrated enhanced antioxidant enzyme activity in 
alveolar macrophages from hamsters following cigarette 
smoke exposure, which resulted in reduced mortality when 
the animals were subsequently exposed to 95% oxygen. 
They speculated that alveolar macrophages undergo an adap-
tive response to chronic oxidant exposure that ameliorates 
potential damage to lung cells from further oxidant stress. 
The mechanism(s) for the induction of antioxidant enzymes 
in erythrocytes, alveolar macrophages, and lungs, by cigarette 
smoke exposure are currently unknown.
Spin traps such as α-phenyl-N-tert-butyl nitrone react 
directly with reactive oxygen and reactive nitrogen species 
at the site of inﬂ  ammation (Chabrier et al 1999). In a recent 
study, Smith and colleagues have shown that intratracheal 
instillation of a catalytic antioxidant, manganese (III) meso-
tetrakis (N,N'-diethyl-1,3-imidazolium-2-yl) porphyrin 
(AEOL 10150 and AEOL 10113) inhibited the cigarette 
smoke-induced inﬂ  ammatory response (decreased number 
of neutrophils and macrophages) in rats after 2 d or 8 weeks 
(6 hours/day, 3 days/week) exposure (Smith et al 2002). 
These compounds also mimic extracellular SOD and catalase, 
scavenging both lipid peroxides and peroxynitrite, and have 
been shown to be effective in a number of animal models 
of lung disease.
It has been shown that SOD mimetic M40419 blocked the 
development of emphysema and signiﬁ  cantly reduced lung 
markers of oxidative stress in an animal model (Tuder et al 
2003). Animal studies have shown that recombinant SOD 
treatment can prevent the neutrophil inﬂ  ux to the airspaces 
and CXCL8 release induced by cigarette smoking through a 
mechanism involving down regulation of NF-κB (Nishikawa 
et al 1999). This further substantiate the idea that generation 
of compounds with anti-oxidant enzyme properties may be 
able to act as novel anti-inﬂ  ammatory drugs by regulating 
the molecular events in COPD.
Development of anti-inﬂ  ammatory 
therapies
NF-κB inhibitors
Studies with IκBα mutants (Baldwin 1996; Ghosh et al 
1998) gave the ﬁ  rst evidence that NF-κB pathway could be 
speciﬁ  cally inhibited. Signal-induced phosphorylation and 
degradation of cytoplasmic IκBα is required for NF-κB 
pathway activation. However, an IκBα protein with muta-
tions at serine-32 and 36 is not phosphorylated by IKK (IκBα 
kinase) and therefore not degraded by the proteasome. This 
IκBα mutant or super-repressor exerts its negative effect by 
sequestering NF-κB in the cytoplasm and thus prevents the 
induction of speciﬁ  c NF-κB target genes.
Another novel way whereby NF-κB activity may be 
regulated is by the use of inhibitors of proteasome function, 
which can reduce the degradation of IκB and thus prevent 
NF-κB activation (Baldwin 1996; Ghosh et al 1998). A series 
of peptide aldehydes such as MG101, MG132, and MG115, 
make up a family of agents that inhibit the protease activity 
of the proteasome. Lactacystin, another class of proteasome 
inhibitor, blocks proteolytic activity by acylating a threonine 
residue in one of the key proteasome subunits. Furthermore, 
a group of boronic acid peptides, including PS-341, are 
extremely potent inhibitors of proteasome function (Adams 
et al 1999), thus inhibiting activation of the NF-κB pathway. 
It is also possible that inhibitors of the ubiquitin ligase that 
mediates IκB ubiquitination may be a useful target in prevent-
ing proteasome degradation of IκB. Thus, a wide variety of 
potential inhibitors of proteasome function may have a thera-
peutic role in anti- NF-κB pathway dependent strategies.
Certain natural antioxidants/products such as ﬂ  avonoids/
polyphenols quercetin, curcumin, resveratrol, and myricetin International Journal of COPD 2007:2(3) 218
de Boer et al
are also known to mediate their anti-inﬂ  ammatory properties 
through down-regulation of the NF-κB pathway (Tsai et al 
1999; Holmes-McNary and Baldwin 2000). For example, 
resveratrol, which is found in red wine, can inhibit NF-κB 
activity and induce apoptosis in transformed cells, which may 
reduce mortality from coronary heart diseases, certain cancers 
and inﬂ  ammatory diseases (Holmes-McNary and Baldwin 
2000). Resveratrol has strong inhibitory effects on iNOS 
expression and NO generation in activated macrophages (Tsai 
et al 1999). Since treatment of macrophages with resveratrol 
blocks LPS-induced phosphorylation and degradation of 
IκBα to decrease NF-κB DNA binding activity, is sugges-
tive of the fact that its anti-inﬂ  ammatory effects may be due 
at least in part to the inhibition of NF-κB-dependent NO 
synthesis (Tsai et al 1999). Thus several of the biological 
activities of ﬂ  avonoids may be mediated by their inhibition 
of the NF-κB pathway.
Thus it is evident that there are several possible approaches 
to inhibition of NF-kB, including gene transfer of IκB, inhibi-
tors of IκB kinases (IKK), NF-κB-inducing kinase and IκB 
ubiquitin ligase, which regulate the activity of NF-κB, and 
inhibit the degradation of IκB (Delhase et al 2000). The most 
promising approach however, may be the inhibition of IKK-2 
by small molecule inhibitors (Castro et al 2003) (Table 2), 
which suppress the release of inﬂ  ammatory cytokines and 
chemokines from alveolar macrophages (Jazrawi et al 
2003). This in particular might be more effective in COPD, 
particularly since alveolar macrophages are resistant to the 
anti-inﬂ  ammatory actions of corticosteroids (see HDACs 
modiﬁ  ers). It is however, of concern that long-term inhibition 
of NF-κB, with effective inhibitors may result in immune 
suppression and therefore impair host defenses. This concern 
is validated from a study that mice lacking NF-κB genes 
succumb to septicemia. However, alternative modulation of 
pathways of NF-κB activation via kinases other than IKK 
might be a more safer approach in inﬂ  ammatory disease 
and would have less potential effect on innate and adaptive 
immune responses (Nasuhara et al 1999).
PDE4 inhibitors
Phosphodiesterase 4 (PDE4) is the predominant PDE isoen-
zyme in most inﬂ  ammatory cells thought to have a role in the 
pathogenesis of COPD (Figure 2). Its activity is elevated in 
lung macrophages from COPD patients (Barber et al 2004). 
In contrast to steroids that have a limited anti-inﬂ  ammatory 
efﬁ  cacy in cigarette smoke models both in the mouse and 
guinea pig, there are increasing numbers of studies document-
ing the in vivo efﬁ  cacy of PDE4 inhibitor in animal models of 
COPD. There are at least currently ﬁ  ve oral PDE4 inhibitors 
in clinical development for COPD, one of which is suspended 
(C1393 in phase II, from Merck) (see Table 2). A major hurdle 
in their development has been to overcome their side effects 
which include nausea, emesis, and headache.
In 24 weeks Phase multi-center III trails in COPD patients 
(RECORD trial), oral administration of roﬂ  umilast or cilo-
milast improved pre- and post-bronchodilator FEV1 (Rabe 
et al 2005; Rennard et al 2006). The health-related quality 
of life (SGRQ) was also improved when compared with the 
placebo control. In addition, exacerbation frequency was 
lower in drugs group than in the placebo group.
The relationship between these improvements in 
clinical outcome and potential anti-inﬂ  ammatory activ-
ity has been investigated in a single study (Gamble et al 
2003; Grootendorst et al 2005). After a 4-week treatment 
with roﬂ  umilast post-bronchodilator FEV1 improved by 
68.7 ml compared with placebo. Treatment with roﬂ  umilast 
signiﬁ  cantly reduced the absolute numbers of neutrophils 
and eosinophils of sputum. These were paralleled with by 
a reduction in CXCL8 and neutrophil elastase. Although a 
12 weeks treatment with cilomilast had no effect on sputum 
neutrophils, macrophages, elastase, CXCL8 or lung funtion, 
bronchial biopsies demonstrated that cilomilast treatment was 
associated with signiﬁ  cant reductions in CD8+ T lymphocyte 
and CD68+ cells. The results showed that related outcomes 
observed in longer term trials could be due, at least in part, 
to anti-inﬂ  ammatory activity of drugs.
In an attempt to reduce the potential for systemic side 
effects and to administer relatively higher doses to the lung, 
inhaled PDE4 inhibitors are being developed. GSK842470 
(AWD-12-281) was licensed from Elbion and reached Phase 
II for asthma and COPD but there have been unconﬁ  rmed 
reports that it had no advantage over oral PDE4 inhibitors. 
This compound no longer appears on GSK’s pipeline but 
remains in development for rhinitis by Elbion. Currently, GSK 
(SB256066, Phase I) and Pﬁ  zer (Phase II) are reported to have 
inhaled PDE4 inhibitors in clinical development for COPD.
Experimental data suggest that PDE4D inhibition is one 
likely cause of the side effects of the orally-delivered com-
pounds, while PDE4B is a therapeutically relevant target. 
Therefore, PDE4 subtype inhibitors eg, PDE4B for treatment 
of COPD is being studied by Plexxikon.
MAPK p38 inhibitors
MAPKs play a key role in chronic inﬂ  ammation and several 
complex enzyme cascades have now been deﬁ  ned (Johnson 
and Lapadat 2002). One of these, the p38 MAPK pathway, is International Journal of COPD 2007:2(3) 219
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activated by cellular stress and regulates the expression of a 
wide variety of inﬂ  ammatory cytokines that include CXCL8, 
TNFα and MMPs (Meja et al 2000). Small molecule inhibitors 
of MAP kinase p38, such as SB 203580, SB 239063 and RWJ 
67657 having a broad range of anti-inﬂ  ammatory effects have 
been developed (Kumar et al 2003) (Table 2). Administration 
of SB203580 has beneﬁ  cial effects in animal disease models 
such as collagen-induced arthritis and endotoxin-induced 
septic shock (Lee et al 1999). p38 has also been shown 
to upregulate cytokine production by several independent 
mechanisms, including direct phosphorylation of transcription 
factors, and direct or indirect (through downstream kinases 
such as MAPKAPK2) stabilization and increased translation 
of mRNAs containing 3% untranslated region adenylate/
uridylate-rich elements (AREs) by phosphorylation of ARE-
binding proteins (Dean et al 2004; Briata et al 2005; Hitti et al 
2006). These observations have attracted interest in p38 as 
a molecular target in the treatment of inﬂ  ammatory human 
diseases. MAPK p38 has 4 isozymes. Each inhibitor has its 
own speciﬁ  city towards one of more of these isozymes, caus-
ing differential effects Studies in healthy volunteers given 
p38α/p38β inhibitors found reductions in pro-inﬂ  ammatory 
cytokine secretion from ex-vivo LPS-stimulated peripheral-
blood mononuclear cells (PBMCs) (Parasrampuria et al 
2003), and decreased LPS-induced pro-inﬂ  ammatory cytokine 
production, neutrophil and endothelial-cell activation in vivo. 
SB239063 on the other hand reduces neutrophil inﬁ  ltration 
and the concentrations of IL-6 and MMP-9 in BALF of rats 
after endotoxin inhalation, suggesting its potential as an anti-
inﬂ  ammatory agent in COPD (Underwood et al 2000).
The potential therapeutic utility of p38 MAPK inhibition 
in respiratory disease has been supported by data generated 
in a range of pulmonary inflammatory models in vivo 
including LPS induced pulmonary neutrophilia (Haddad 
et al 2001), bleomycin induced ﬁ  brosis (Matsuoka et al 
2002), and antigen induced eosinophilia (Underwood et al 
2000). A recent study demonstrated the efﬁ  cacy of p38α 
MAPK inhibitor, SD282, in mouse COPD models (Fitzgerald 
et al 2006). In this model, SD-282 inhibited cigarette 
smoke induced pulmonary neutrophilia and macrophage 
recruitment. Although a number of oral p38 MAPK inhibitors 
are in clinical development for arthritis and cancer only two 
compounds are currently in development for COPD. GSK-
681323 is currently in a 4 week Phase II trial where the 
efﬁ  cacy outcome measures include lung function, sputum 
and serum biomarkers, including CRP. GSK-85633 is in 
Phase I. Although it is likely that such a broad spectrum 
anti-inﬂ  ammatory drug might ensue some toxicity or impair 
natural immune responses, but inhalation route might be a 
feasible therapeutic approach.
Elastase inhibitor
Neutrophil elastase is a serine protease that is synthesized in 
the neutrophils and secreted following neutrophils activation. 
One of the major actions of neutrophil elastase is its ability 
to degrade matrix proteins and appears to be a key enzyme 
in the development of hereditary due to α-antitrypsin deﬁ  -
ciency. Although its role in the development of non hereditary 
emphysema is currently unclear it also has a broad range of 
actions that are consistent with it having a pro-inﬂ  ammatory 
role in COPD pathogenesis (Shapiro et al 2003; Chughtai and 
O’Riordan 2004). Neutrophil elastase can increase MMPs 
activity by directly activating MMPs such as MMP-9 (Ferry 
et al 1997) and by inactivating the endogenous MMP inhibi-
tor, TIMP (Okada et al 1988), thus potentially enhancing the 
role of MMPs in COPD. Neutrophil elastase has also been 
reported to stimulate mucin secretion and modulate apoptosis 
of human lung epithelial cells. Therefore, neutrophil elastase 
may play a role in emphysema and lung remodeling through 
matrix degradation and by inducing apoptosis.
In cigarette smoke models, neutrophil elastase knockout 
mice are protected from emphysema development and this 
effect is accompanied by an inhibition of both neutrophils and 
macrophages recruitment (Shapiro et al 2003). Treatment with 
α1-antitrypsin inhibited emphysema development and reduced 
recruitment of pulmonary neutrophils and macrophages (Churg 
et al 2003; Pemberton et al 2006). Similarly, a small molecule 
neutrophil elastase inhibitor, ZD0892, reduced cigarette smoke 
induced emphysema and pulmonary cells recruitment in a 
guinea pig model (Wright et al 2002). These studies suggest 
inhibition of neutrophil elastase can be anti-inﬂ  ammatory in 
addition to preventing emphysema development.
The search for potent, safe oral inhibitors of neutrophil 
elastase has been going on for over 20 years and many of the 
compounds that progressed into clinical development failed 
because of poor pharmacokinetics and a low therapeutic 
index. Subsequently, tripeptidyl triﬂ  uoromethyl ketones 
were developed that had a better oral proﬁ  le, although 
these molecules were not fully optimized for oral delivery 
(Edwards et al 1997). Also monocyclic b-lactam neutrophil 
elastase inhibitors were identiﬁ  ed (Vincent et al 1997). More 
recently, both GSK (GSK-311366) and ONO Pharmaceu-
ticals (ONO6818) have had oral compounds in Phase I/II. 
However, they failed in early clinical trials and thus far no 
oral elastase inhibitors have been evaluated fully in Phase II 
COPD trials. The AstraZeneca protease inhibitor AZD3342 International Journal of COPD 2007:2(3) 220
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(thought to be an elastase inhibitor) is scheduled to progress 
to Phase II studies in the second half of 2006 and Bayer 
GmbH has an inhibitor in Phase I but the outcomes of these 
trials are still awaited.
Protein inhibitors of neutrophil elastase administered 
via nebulisation are also being pursued and supportive data 
has been obtained for inhaled recombinant α1-antitrypsin in 
mouse cigarette smoke models. The probability of inhaled 
combination products consisting of elastase inhibitors with 
bronchodilators is low. However, the opportunity for safe 
long acting inhaled elastase inhibitors with low systemic 
bioavailability that are suitable for combination with bron-
chodilators is being pursued by Argenta Discovery.
HDACs modiﬁ  ers
NF-κB being a pro-inﬂ  ammatory transcription factor, on 
activation binds to speciﬁ  c recognition sequence motifs in DNA 
and subsequently interacts with a multitude of co-activator 
molecules, such as cAMP-response-element-binding 
protein (CREB), CREB-binding protein (CBP), p300 and 
p300/CBP-associated factor (pCAF). These co-activators 
act as molecular switches of transcription and acetylate 
histones by their intrinsic histone acetyltransferase (HAT) 
activity (Ogryzko et al 1996; Roth et al 2001). Acetylation 
of core histones allow DNA unwinding and thus access to 
wide variety of transcription factors (Roth et al 2001). The 
transcriptional process can be reversibly switched off by 
deacetylation of acetylated histones, thus rewinding the 
exposed DNA, consequently leading to gene silencing. The 
deacetylation of acetylated histones is brought about by 
histone deacetylases (HDACs), which act as co-repressors, 
in association with other co-repressor proteins that are 
concomitantly recruited. Since all inﬂ  ammatory processes 
involve acetylation and deacetylation of histones (chromatin 
remodeling) (Barnes 2006), HDACs therefore are attractive 
targets for anti-inﬂ  ammatory therapies.
Ito and co-workers have shown a role for histone acetylation 
and deacetylation in IL-1β-induced TNF-α release in alveolar 
macrophages derived from cigarette smokers (Ito et al 2001). 
They have also suggested that oxidants may play an important 
role in the modulation of HDAC and inﬂ  ammatory cytokine gene 
transcription. Furthermore, we have shown that both cigarette 
smoke/H2O2 and TNF-α caused an increase in histone acetyla-
tion (HAT activity) leading to CXCL8 expression in monocytes 
and alveolar epithelial cells both in vitro and in vivo in rat lungs 
(Rahman et al 2002; Marwick et al 2004; Moodie et al 2004).
Glucocorticoid suppression of inflammatory genes 
requires recruitment of HDAC2 to the transcription 
activation complex by the glucocorticoid receptor (Ito et al 
2001; Rahman et al 2004). This results in deacetylation of 
histones and a decrease in inﬂ  ammatory gene transcription. 
A reduced level of HDAC2 was associated with increased 
proinﬂ  ammatory response and reduced responsiveness to 
glucocorticoids in alveolar macrophages obtained from 
smokers (Ito et al 2001; Rahman et al 2002; Marwick 
et al 2004; Moodie et al 2004; Rahman et al 2004). Culpitt 
and co-workers have shown that cigarette smoke solution 
stimulated release of CXCL8 and GM-CSF, which was 
not inhibited by dexamethasone, in alveolar macrophages 
obtained from patients with COPD compared to that of 
smokers (Culpitt et al 2003). They suggested that the lack of 
efﬁ  cacy of corticosteroids in COPD might be due to steroid 
insensitivity of macrophages in the respiratory tract. Thus, 
the cigarette smoke/oxidant-mediated reduction in HDAC2 
levels in alveolar epithelial cells and macrophages will not 
only increase inﬂ  ammatory gene expression but will also 
cause a decrease in glucocorticoid function in patients with 
COPD. HDAC2 activity has also been measured in bronchial 
biopsies and alveolar macrophages from COPD patients 
and smoking control, demonstrating a signiﬁ  cant decrease 
in HDAC2 activity, the magnitude of which increased with 
severity of disease (Ito et al 2005) (Table 1). Moreover, 
protein expression of HDAC2 was decreased in a similar 
manner in COPD patients.
Consequently, a potential means by which to treat COPD 
would be to increase HDAC2 expression and activity such 
that steroids regain their anti-inﬂ  ammatory activity. We 
have shown that co-incubation of cells with NAC and H2O2 
protects HDAC2 from down-regulation and reduction of 
speciﬁ  c activity (Moodie et al 2004). In addition, it has been 
reported that theophylline has a similar effect in lung macro-
phage cells, increasing HDAC2 expression and re-sensitising 
the cells to steroids (Cosio et al 2004). Similar data were 
obtained for curcumin, a dietary polyphenols, in restoration 
of steroid efﬁ  cacy (unpublished data). Alternative means of 
upregulating HDAC2 activity would be of great interest for 
potential combination therapies of the future.
Cytokine and chemokine antagonists
Several recent reviews point to the development of novel 
antagonists of cytokines, chemokines or their receptors (De 
Boer 2005; Chung 2006; De Boer et al 2007). These mol-
ecules may reduce gene expression, impair production or 
secretion of mature proteins, antagonize binding of cytokines 
and chemokines to their receptors or inhibit receptor signal 
transduction (Table 2). Antibodies and solubilized receptors International Journal of COPD 2007:2(3) 221
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like TNFR often scavenge solubilized cytokines and chemo-
kines, or prevent binding of these proteins to their receptors. 
Small molecules 1) prevent binding of cytokines and che-
mokines to their receptors by non-activating mimicking of 
cytokines or chemokines, or 2) prevent intracellular signal 
transduction activation, or 3) interfere with gene expression 
and translation by direct inhibition of transcription factors 
(like IKK2 inhibition) or mRNA binding via small interfer-
ence (si) RNA or antisense mRNA.
TNFα and receptors antagonists
As a major proinﬂ  ammatory cytokine TNFα and its receptors 
TNFR1 (or: TNFR p55) and TNFR2 (or: TNFR p75) seem 
to play an important role in many chronic diseases includ-
ing COPD and asthma. Therefore, several drugs have been 
developed to reduce TNFα levels, of which some have been 
approved by eg, the Federal Drug Administration (FDA) for 
treatment of RA, ankylosing spondylitis, Crohn’s disease, or 
psoriasis. These approved drugs include etanercept (soluble 
human TNFR2), inﬂ  iximab (chimeric human/mouse IgG1 
antibody against TNFα), and adalumimab (human IgG1 
antibody against TNFα). Many others are being developed in 
order to enhance efﬁ  cacy, reduce side effects due to frequent 
subcutaneous injection, increase bioavailability or protection 
to proteolytic degradation by coupling to polyethylene glycol 
(PEG) chains, or reduce immunogenicity by humanization of 
antibodies or designing small molecules. Some examples are 
given in Table 2. Recent clinical trial phase II studies demon-
strated that patients with moderate to severe asthma may proﬁ  t 
from treatment with either of these drugs. Three infusions of 
inﬂ  iximab over 6 weeks reduced the number of exacerbations 
as well as sputum levels of TNFα, IL-6, CXCL8 and CXCL10 
but not peak expiratory ﬂ  ow (PEF) or inﬂ  ammatory cell count 
in sputum of patients with moderate asthma (Erin et al 2006). 
Other studies demonstrated that twice-weekly treatment with 
etanercept during 10 to 12 weeks improved the bronchial 
hyperresponsiveness (BHR, expressed as PC20), post-broncho-
dilator FEV1 and the quality of life of patients with refractory, 
severe asthmatic patients (Howarth et al 2005; Berry et al 
2006). Treatment of asthmatics with Marimastat, an inhibitor 
of TNFα and MMP activation, also reduced BHR but failed 
to signiﬁ  cantly reduce sputum inﬂ  ammatory cell numbers, 
asthma symptoms, FEV1 or bronchodilator use (Bruce and 
Thomas 2005). In contrast to asthma, 2 studies showed that 
treatment of COPD patients with 3 infusions of inﬂ  iximab 
over 6 to 24 weeks did not result in any signiﬁ  cant improve-
ment of lung function, airway inﬂ  ammation, or quality of life 
(Abdelhady et al 2005; van der Vaart et al 2005; Rennard et al 
2007). Treatment may have some beneﬁ  cial effect on physical 
endurance seen by the 6 minute walking distance test (Rennard 
et al 2007). This ineffectiveness may be due to a rather short 
treatment period, the choice of inﬂ  iximab over other drugs, or 
to the complex or less signiﬁ  cant role of TNFα in progressed 
COPD. Future studies should sort out whether long-term 
treatment or treatment with different TNFα antagonists are 
beneﬁ  cial to all COPD patients or only a speciﬁ  c population 
of COPD patients (Rennard et al 2007).
CXCL1, CXCL8, and receptors antagonists
As previously mentioned (De Boer 2005), several CXCR2 
and CXCL8 antagonists are available, some of which were 
in clinical trial for COPD. Updated information shows that 
either the testing of these drugs is discontinued (like the anti-
body ABX-IL-8 against human CXCL8) or is not to be found 
in the public domain. Hence, little is known yet on treatment 
of patients with COPD with CXCL8 or CXCR2 antago-
nists. The small molecule CXCR2 antagonist SB-656933 
(by GSK) has recently been demonstrated to inhibit the 
CXCL8-induced expression of CD11b molecules on periph-
eral blood neutrophils from COPD patients (Nicholson et al 
2007). The antagonist was mentioned to enter clinical trial 
studies for COPD in 2005, but is not so in GSK’s pipeline 
of 2006. AZD-8309 is a pyrimidine derivate currently in 
phase I clinical trial for COPD and phase II for RA. Data 
from these studies have not yet been published. SB-265610 
is a small molecule inhibiting CXCR2. Studies demonstrated 
that hyperoxia in newborn rats led to pulmonary inﬂ  am-
mation by neutrophils and the formation of ROS and RNS 
mediating impaired lung development and lipid peroxida-
tion (Auten et al 2001; Liao et al 2006). Treatment with 
SB-265610 reduced airway neutrophilia, radical formation, 
lipid peroxidation and protein nitration, as well as improved 
conservation of lung development and lung function. This 
points to the importance of reducing neutrophilia in order 
to reduce reactive species formation, peroxidation or nitra-
tion and tissue destruction or alterations. Data from other 
studies supported the effectiveness of CXCL8 or CXCR2 
antagonists in reducing neutrophilia in vivo in rodents and 
inhibition of neutrophil activation and degranulation in vitro 
(De Boer 2002, 2005). These data point to the potential need 
for development of novel antagonists of CXCR1, CXCR2 or 
their ligands CXCL1 and CXCL8. Recent studies showed 
that novel thiazolopyrimidine, cyclobutenedione (eg, SCH 
527123), or imidazolylpyrimidine CXCR2 antagonists had a 
good oral bioavailability in rats with reasonable pharmaco-
kinetics (half life of at least 1.2h) (Baxter et al 2006; Dwyer International Journal of COPD 2007:2(3) 222
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et al 2006; Ho et al 2006), and inhibition of CXCL1- or 
CXCL8-induced chemotaxis of cells (Baxter et al 2006; 
Dwyer et al 2006).
CCL2 and CCR2 antagonists
The humanized monoclonal antibody MLN1202 (by 
Millennium) against CCR2 is currently in phase II for treat-
ment of chronic inﬂ  ammatory diseases like multiple sclerosis 
and artherosclerosis. Clinical data from these studies have 
not yet been published. Other inhibitors in clinical trial 
include the small molecule CCR2 inhibitors CCX915 (by 
ChemoCentryx) for multiple sclerosis (phase I), INCB3284 
(by Incyte/Pﬁ  zer) which is in phase IIa for treatment of RA, 
and the monoclonal antibody ABN912 against CCL2 (by 
Novartis) for COPD (phase I) and RA (phase II). Recently, 
patients with RA did not clinically and immunohistologically 
respond to a 2-week treatment with ABN912 (Haringman 
et al 2006). Serum levels of CCL2 increased clearly after 
treatment (doses higher than 1 mg/kg bw), and chemotactic 
complexes of the antibody with CCL2 were formed. This may 
hamper the treatment of patients with COPD, however these 
results have to be awaited. Several other compounds based 
on butyramides or γ-aminoamides were recently developed 
as speciﬁ  c CCR2 antagonists with a good oral bioavailablity 
in rats (Butora et al 2006; Pasternak et al 2006). Others are 
in preclinical phase, including INCB8696, JNJ-27553292, 
SKL-2841 and INCB3344. INCB3344 is a rodent CCR2 
small molecule antagonist (Brodmerkel et al 2005). The 
compound was shown to inhibit macrophage inﬂ  ux in a 
mouse model for delayed hypersensitivity.
Other anti-inﬂ  ammatory agents for COPD include ion 
channel blocker (P2X7, Phase II, from AstraZeneca), mono-
clonal antibody to IL-1β (Phase I, from Novartis), inhibitors of 
5-lipoxygenase (PEP03 inhaled, Phase II, from PharmaEngine) 
and iNOS inhibitors (GW-274150, Phase II, from GSK).
Target growth factors
Several studies pointed to the involvement of VEGF/VEGFR 
in pulmonary and vascular remodeling and inflamma-
tion. Therefore, VEGF inhibitors may be of potential use 
for treatment of vascularization, as seen in asthma or in 
speciﬁ  c subtypes of COPD, such as chronic bronchitis, 
but not emphysema (Marwick et al 2006; De Boer et al 
2007). Several drugs have been developed to reduce tumor 
growth and metastasis by impairing the neovascularization. 
Antagonists include those in clinical trials and in preclinical 
investigations. Among those in clinical trial are VEGF-Trap, 
bevacizumab (or: Avastin), CEP-7055, VEGF Trap, and 
PTK787 (Ferrara et al 2003). However, little is known yet 
of side effects or their efﬁ  cacy in the treatment of COPD. In 
addition, in patients with emphysema for example, inhibi-
tors of apoptosis are needed whereas in contrast to chronic 
bronchitis, expression of hypoxia-inducible factor, VEGF, 
and VEGFR2 may be stimulated to overcome endothelial 
and epithelial cell death and improve vascular restoration 
(Voelkel and Coll 2003). Hence, treatment with VEGF/
VEGFR inhibitors should be further investigated and may be 
restricted to speciﬁ  c subtypes of chronic lung diseases.
As discussed aforementioned, TGFβ1 expression was 
increased in COPD as compared to smokers without COPD, 
inhibition of TGFβ-mediated pathway may hence be a target 
for therapeutic intervention. However, almost all of TGFβ1 
antagonists are still in preclinical development. Hence, little 
can be discussed yet on clinical applicability.
Concluding remarks
In order to reverse continuing damage and remodeling needs 
stopping exposure to tobacco smoke by many patients with 
COPD. However, after smoking cessation inﬂ  ammation goes 
on which may hamper tissue repair. The ongoing inﬂ  ammation 
may be due to an autoimmune component and/or epigenetics 
alterations. However, not all patients with COPD are smokers 
but do suffer from tissue damage and/or remodeling. Hence, 
an effective treatment of patients with COPD not only needs 
stopping exposure to toxic compounds like smoke, but also 
needs reduction of excessive inﬂ  ammation, oxidative status, 
and stimulation of parenchymal and/or airway repair (Leff 
2006). This needs further development and testing of therapeu-
tic drugs antagonizing a low antioxidant status, inﬂ  ammation, 
and excessive remodeling. There are several small molecule 
compounds in clinical trials that target oxidant signaling or 
quench oxidants derived from inﬂ  ammatory cells and cigarette 
smoke. Regarding inhibition of inﬂ  ammation several drugs 
have been used successfully for treating different chronic 
inﬂ  ammatory diseases, but not yet for COPD. As pointed out 
in this review, success may be hindered by the complexity of 
actions of eg, chemokines and antioxidants, or by a low efﬁ  -
cacy and bioavailability of the drugs. Whereas more insight is 
needed in the pathogenesis of COPD or its subtypes, individu-
alized combination therapy with such novel and speciﬁ  c anti-
inﬂ  ammatory and anti-oxidant drugs may be advantageous to 
patients with speciﬁ  c phenotypes of the disease.
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